Realizing the urgent unmet medical need created by the 2019 SARS-CoV-2 pandemic, Relief mounted a swift plan of action to respond to one of the largest healthcare disasters of our time by rapidly advancing our proprietary asset RLF-100™ into clinical development and towards approval in COVID-19 induced lung injury. Within a year the results of a Phase 2b/3 trial with IV RLF-100™ performed by NeuroRX, a company partner of Relief, have become available, demonstrating, according to NeuroRX, encouraging outcomes. Several additional clinical studies with RLF-100™ in IV or inhaled formulation have been initiated.